Abstract
An improvement in survival time, but cardiotoxicity remains a concern.
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / genetics
-
Breast Neoplasms / mortality
-
Chemotherapy, Adjuvant
-
Female
-
France
-
Humans
-
Receptor, ErbB-2 / genetics
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Receptor, ErbB-2